Compared with adults aged 65 and older, those aged 18 to 64 are more affected by long COVID neurologic symptoms.

Emblaveo is a fixed-dose IV treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Three recommendations suggest monotherapy options for preventing episodic migraine headache in outpatient settings ...

During the study, there was a steady increase in the PARF for CUD associated with schizophrenia, with no accelerations observed after cannabis policy changes. After medical cannabis liberalization, ...

Researchers sought to examine outcomes following in-hospital cardiac arrest among Hispanic and Asian patients.

Dementia cases had lower BMI and waist circumference and faster declines; HDL levels generally higher predementia ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

High school seniors in New England from historically underserved populations can apply for the Mary Eliza Mahoney Scholarship if they are members of the New England Regional Black Nurses Association ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...

Mendelian randomization analysis of genome-wide association study data suggests schizophrenia and major depressive disorder may cause constipation. Constipation, a common and often debilitating ...